Evaluation of the BT-1 serum assay for breast cancer.

The BT-1 assay which identifies a novel breast tumor associated serum analyte was performed for 143 patients previously diagnosed with breast cancer. Mucin tumor markers CA15-3/CA27-29 values were available for 50 patients and there was very minor overlap between patients positive by both tests. Patients' follow-up clinical status at sample draw was compared to BT-1 assay results.

Clinical analysis of the novel breast cancer serum assay BT1.

In an effort to define possible clinical relationships to the BT1 serum assay, a retrospective study population including both Caucasian and African American breast cancer patients was tested. Test results were compared to clinical information provided by the Virginia Cancer Registry. The 64 patients, ages 29 through 69, had a wide range of BT1 values which were not attributable to race or age.

Secretion of human monoclonal antibody after fusion of an immortal T cell line and lymphocytes from the peripheral blood of a patient with colon carcinoma.

A series of human hybridomas were derived by the fusion of the immature T cell line, JM, and lymphocytes from the peripheral blood of a colon carcinoma patient in long term remission who was shown to produce anti-tumor antibody. Five of the hybridomas have been selected for further study. These hybridomas express the T cell surface markers CD2, CD3, CD4, and CD8.

The use of a totally human monoclonal antibody for the staining of primary and metastatic human breast tumors.

Numerous murine monoclonal antibodies reactive with human mammary tumor cells have been developed and used for identification of various breast tumor antigens. The problems encountered with these murine monoclonal antibodies include poor sensitivity and cross reactivity with normal tissue. We report here the use of a human monoclonal antibody (JDB1) as a more sensitive and specific method for staining of paraffin-embedded breast carcinoma tissue.

Human monoclonal antibody JDB1 reacts with cytoplasmic and membrane bound antigens present on a variety of human breast tumor cell lines.

The human monoclonal antibody JDB1 was examined for reactivity to five breast cancer cell lines as well as normal fibroblasts. The JDB1 clone secretes both IgG3 and IgM antibody. In these studies both the total antibody (containing IgG3 and IgM) as well as the purified IgG3 and IgM fractions were examined for tumor cell binding reactivity.